[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349819-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-349819-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","perioperative-chemoimmunotherapy-for-patients-with-gastric-or-gastroesophageal-junction-cancer-a-systematic-review-and-meta-analysis","Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer - a systematic review and meta-analysis","","Addition of immune checkpoint inhibitors (ICIs) to perioperative therapy for resectable gastric or gastroesophageal junction (GEJ) cancers may improve outcomes, yet pivotal trials have reported conflicting survival results. This meta-analysis systematically evaluated randomized controlled trials comparing ICIs plus chemotherapy with chemotherapy alone. Outcomes included pathological complete response, event-free survival, overall survival, and treatment-related adverse events, pooled with a fixed-effect model.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/perioperative-chemoimmunotherapy-for-patients-with-gastric-or-gastroesophageal-junction-cancer-a-systematic-review-and-meta-analysis/349819/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/perioperative-chemoimmunotherapy-for-patients-with-gastric-or-gastroesophageal-junction-cancer-a-systematic-review-and-meta-analysis/349819.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"为什么需要研究围手术期化疗联合免疫治疗的效果？","Question",{"text":63,"@type":64},"免疫检查点抑制剂（ICIs）加入可切除胃或胃食管交界（GEJ）癌的围手术期治疗显示潜在益处，但关键临床试验的生存结局存在不一致，因此需要用系统综述和荟萃分析澄清其疗效与安全性。","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"本研究纳入了哪些类型的试验，以及主要结局是什么？",{"text":68,"@type":64},"研究纳入比较ICIs联合化疗与单纯化疗的随机对照试验。主要结局包括病理完全缓解（pCR）、无事件生存（EFS）、总生存（OS）以及治疗相关不良事件（TRAEs）。",{"name":70,"@type":61,"acceptedAnswer":71},"围手术期化疗联合免疫治疗在主要疗效指标上有哪些结果？",{"text":72,"@type":64},"与单纯化疗相比，联合治疗显著提高pCR，并改善EFS与OS。亚组分析显示在PD-L1阳性肿瘤中疗效更明显，而PD-L1阴性患者未观察到显著获益。",{"name":74,"@type":61,"acceptedAnswer":75},"安全性方面，联合治疗是否增加了≥3级治疗相关不良事件？",{"text":76,"@type":64},"研究结果显示，≥3级TRAEs在联合治疗组与对照组之间未见显著增加，提示安全性总体可接受。","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},349819,1790462743,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","JNCI Cancer Spectrum, 2026, 10(1), pkag003  \n[https://doi.org/10.1093/jncics/pkag003](https://doi.org/10.1093/jncics/pkag003)  \nAdvance Access Publication Date: January 24, 2026  \nMeta-Analysis  \nPerioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis  \nReo Omori , MD1, Yu Fujiwara , MD2,3, Kota Tokunaga, MD4, Takumi Sato , MD5, Sarbajit Mukherjee , MD, MS􀀃 ,6  \n1Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan 2Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States  \n3Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan 4Fujita Health University Hospital, Toyoake, Japan  \n5Icahn School of Medicine at Mount Sinai, Morningside Hospital, New York, NY, United States 6GI Medical Oncology, Miami Cancer Institute, Miami, FL, United States  \n􀀃 Corresponding author: Sarbajit Mukherjee, MD, MS, GI Medical Oncology, Miami Cancer Institute, 8900 North Kendall Drive, Miami, FL 33176, United States ([sarbajit.mukherjee@baptisthealth.net](sarbajit.mukherjee@baptisthealth.net)) .  \nAuthor Contributions: R. Omori and Y. Fujiwara contributed equally.  \nAbstract  \nBackground: The addition of immune checkpoint inhibitors (ICIs) to perioperative treatment for resectable gastric or gastroesophageal junction (GEJ) cancers has shown promising results. However, current pivotal trials (KEYNOTE-585 and MATTERHORN) have reported conflicting survival outcomes. To clarify their therapeutic value, we conducted a meta-analysis evaluating the efficacy and safety of adding ICIs to this population.  \nMethods: PubMed, Embase, and major oncology conference abstracts were systematically searched for randomized controlled trials (RCTs) comparing ICIs plus chemotherapy versus chemotherapy alone in patients with resectable gastric or GEJ adenocarcinoma. Outcomes included pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and treatment-related adverse events (TRAEs). Risk differences (RDs) and hazard ratios (HRs) were pooled using a fixed-effect model meta-analysis.  \nResults: Seven RCTs involving 2510 patients were included. Compared with chemotherapy alone, chemoimmunotherapy significantly improved pCR (17.6% vs. 6.1%; RD ¼ 0.11, 95% CI ¼ 0.09 to 0.14, P \u003C .001), EFS (HR ¼ 0.76, 95% CI ¼ 0.66 to 0.86, P \u003C .001), and OS (HR ¼ 0.82, 95% CI ¼ 0.71 to 0.94, P ¼ .005) . Subgroup analyses showed statistically significant efficacy in PD-L1 positive tumors, whereas no significant benefit was observed in PD-L1 negative patients. Grade ≥3 TRAEs were not significantly increased with chemoimmunotherapy (66.1% vs. 62.7%; RD ¼ 0.04, 95% CI ¼ 0.00 to 0.08, P ¼ .08) .  \nConclusions: The addition of ICIs to perioperative chemotherapy improves pathological and survival outcomes in resectable gastric or GEJ cancers, particularly in PD-L1 positive populations, without increasing grade ≥3 TRAEs. These findings support chemoimmunotherapy as a promising curative strategy.  \nIntroduction  \nGastric cancer and gastroesophageal junction cancer are the fifth most common cancers and the fourth most frequent cause of cancer-related mortality globally.1 Despite advances in diagnostic and therapeutic strategies, the prognosis of patients with locally advanced disease remains poor.2 Surgical resection remains the mainstay of curative treatment; however, nearly 75% of patients who underwent surgery alone experienced disease recurrence within 3 years.3 ,4  \nTo improve long-term outcomes, perioperative chemotherapy has become a standard approach for resectable gastric cancer and gastroesophageal junction cancer, supported by landmark trials such as MAGIC and FLOT4 .4 , 5 Nevertheless, the pathological complete response (pCR) rates achieved with chemotherapy alone remain modest with reported rates ranging from approximately 5% to 10%, and long-te","cbCairui9KfWv1aF","https://ap.wps.com/l/cbCairui9KfWv1aF","pdf",1688014,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"为什么需要研究围手术期化疗联合免疫治疗的效果？\",\"answer\":\"免疫检查点抑制剂（ICIs）加入可切除胃或胃食管交界（GEJ）癌的围手术期治疗显示潜在益处，但关键临床试验的生存结局存在不一致，因此需要用系统综述和荟萃分析澄清其疗效与安全性。\"},{\"question\":\"本研究纳入了哪些类型的试验，以及主要结局是什么？\",\"answer\":\"研究纳入比较ICIs联合化疗与单纯化疗的随机对照试验。主要结局包括病理完全缓解（pCR）、无事件生存（EFS）、总生存（OS）以及治疗相关不良事件（TRAEs）。\"},{\"question\":\"围手术期化疗联合免疫治疗在主要疗效指标上有哪些结果？\",\"answer\":\"与单纯化疗相比，联合治疗显著提高pCR，并改善EFS与OS。亚组分析显示在PD-L1阳性肿瘤中疗效更明显，而PD-L1阴性患者未观察到显著获益。\"},{\"question\":\"安全性方面，联合治疗是否增加了≥3级治疗相关不良事件？\",\"answer\":\"研究结果显示，≥3级TRAEs在联合治疗组与对照组之间未见显著增加，提示安全性总体可接受。\"}]","Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer - a systematic review and meta-analysis | PDF",1790085753,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efa6e21b3bac51fb1da95596e2d33092.webp",983,1291,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80848f2d11d5a6c8d71f60008022fea8.webp",982,1290,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ab7167006ac48bfe66c42aa93997197.webp",981,1289,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a153aa9cfea9ee0ba3b4c7fe88061cea.webp",980,1287]